CN101176707A - Carmustine sustained-release implantation agent for curing entity tumour - Google Patents
Carmustine sustained-release implantation agent for curing entity tumour Download PDFInfo
- Publication number
- CN101176707A CN101176707A CNA2007102028853A CN200710202885A CN101176707A CN 101176707 A CN101176707 A CN 101176707A CN A2007102028853 A CNA2007102028853 A CN A2007102028853A CN 200710202885 A CN200710202885 A CN 200710202885A CN 101176707 A CN101176707 A CN 101176707A
- Authority
- CN
- China
- Prior art keywords
- carmustine
- poly
- lactide
- sustained
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 title claims abstract description 227
- 229960005243 carmustine Drugs 0.000 title claims abstract description 226
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 126
- 238000013268 sustained release Methods 0.000 title claims description 93
- 239000012730 sustained-release form Substances 0.000 title claims description 93
- 238000002513 implantation Methods 0.000 title claims description 42
- 239000007943 implant Substances 0.000 claims abstract description 97
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 54
- 229930195725 Mannitol Natural products 0.000 claims abstract description 54
- 239000000594 mannitol Substances 0.000 claims abstract description 54
- 235000010355 mannitol Nutrition 0.000 claims abstract description 54
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 48
- 239000003814 drug Substances 0.000 claims abstract description 43
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 36
- 239000000600 sorbitol Substances 0.000 claims abstract description 36
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 36
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 229920002101 Chitin Polymers 0.000 claims abstract description 14
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 3
- 102000009027 Albumins Human genes 0.000 claims abstract description 3
- 108010088751 Albumins Proteins 0.000 claims abstract description 3
- 102000008186 Collagen Human genes 0.000 claims abstract description 3
- 108010035532 Collagen Proteins 0.000 claims abstract description 3
- 108010010803 Gelatin Proteins 0.000 claims abstract description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920000159 gelatin Polymers 0.000 claims abstract description 3
- 239000008273 gelatin Substances 0.000 claims abstract description 3
- 235000019322 gelatine Nutrition 0.000 claims abstract description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 3
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 3
- 239000000811 xylitol Substances 0.000 claims abstract description 3
- 235000010447 xylitol Nutrition 0.000 claims abstract description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 3
- 229960002675 xylitol Drugs 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 64
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 58
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 58
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 58
- 239000002253 acid Substances 0.000 claims description 56
- 239000011780 sodium chloride Substances 0.000 claims description 30
- 230000001093 anti-cancer Effects 0.000 claims description 17
- 150000003904 phospholipids Chemical class 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000001514 prostate carcinoma Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 6
- 201000010174 renal carcinoma Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 5
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 4
- -1 chrondroitin Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 33
- 238000000034 method Methods 0.000 abstract description 26
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 229920002521 macromolecule Polymers 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 2
- 229940044683 chemotherapy drug Drugs 0.000 abstract 2
- 238000012148 non-surgical treatment Methods 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 229920002567 Chondroitin Polymers 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 231100000057 systemic toxicity Toxicity 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 22
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 238000005303 weighing Methods 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011580 nude mouse model Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a slow-release implant agent of carmustine for tumor treatment, which is characterized in comprising effective amounts of carmustine, slow-release excipients and releasing regulatory agents in the slow-release implant agent. The excipients comprise macromolecules which are biologically compatible and degradable, mainly p (LAEG-EOP) and p (DAPG-EOP). The releasing regulatory agents are selected from one or more items from mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen, chondroitin, gelatin and albumin. The slow-release implant agent slowly releases carmustine on the local tumor in the process of degradation and absorption, so the argent can evidently reduce the systemic toxicity and simultaneously apply to the effective drug concentration control on the local tumor. Therefore, the argent can be applied separately or combined with the non-surgical treatments such as chemotherapy drug and radiotherapy, which can be also widely used for tumor treatment of different phases, not only selectively improving the drug concentration on local tumor but also reinforcing the therapeutic effect of non-surgical treatments such as chemotherapy drug and radiotherapy.
Description
(1) technical field
The present invention relates to a kind of carmustine sustained-release implantation agent for the treatment of entity tumor, belong to technical field of pharmaceuticals.
(2) background technology
Though the research about cancer has obtained bigger progress, its mortality rate still occupies the prostatitis of the various common causes of the death.In China 1,600,000 people's cancer strickens are arranged approximately every year, nearly 1,300,000 people die from cancer, account for 1/5th of total death toll.Cancer morbidity rises year by year and is rejuvenation trend, has data to show that in less than the time in 20 years, China's cancer morbidity has risen 69%, and mortality rate has increased by 29.4%.According to World Health Organization's recent statistics, will increase by 50 percent to the year two thousand twenty whole world cancer morbidity, number of the infected increases to 15,000,000.Therefore, inquire into the focus that a kind of effective treatment method for cancer or medicine have become present research.
For many years, carmustine is used as the choice drug as the treatment cerebroma always.The effect that is used for the treatment of other tumor separately is unclear.Though unite some tumor tool is had certain effect, limited its clinical practice by the caused whole body toxic and side effects of conventional route administration with other anticarcinogen.
For improving its general toxicity and to the therapeutic effect of kinds of tumors, the local slow free list reveals great superiority, sees Chinese patent (ZL200410035923.7; ZL200410035926.0; ZL200410035924.1; ZL200410035927.5; ZL200510042434.9; ZL200510042433.4; ZL2005100424800).Yet existing slow releasing agent is a slow-released carrier with polyester such as PLA and PLGA (polyesters) family macromolecule, and its release cycle is shorter, and is relatively poor for the tumor cell effect that enters rest period, therefore relatively poor to the effect of remaining tumor cell.
(3) summary of the invention
Based on examination to prior art, the present invention has carried out a large amount of comparisons to existing adjuvant and the slow release regulator that may influence drug release, found that carmustine is in poly-phospholipid macromolecule, particularly when poly-(L lactide-co-etherophosphoric acid (p (LAEG-EOP)), under the condition that poly-(L-lactide-co-phosphoric acid propyl ester) poly-phospholipid such as (p (DAPG-EOP)) and slow release regulator exist, has more stable release behavior, to cervical cancer, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, entity tumor such as colon cancer and rectal cancer has comparatively significantly action effect.Discover that further the carmustine local sustained release also has good therapeutical effect to the outer entity tumor of other craniums such as thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
No matter be inside and outside drug release behavior or general toxicity or therapeutic effect, the interpolation of the slow release regulator of given dose all shows beyond thought effect.
The present invention is directed to the deficiencies in the prior art, a kind of sustained-release implant is provided, be used for the treatment of multiple entity tumor.
The present invention treats the sustained-release implant of entity tumor, comprises anticancer effective component and slow-release auxiliary material, and wherein anticancer effective component is carmustine (Melphalan or Melfalan).
This sustained-release implant is made up of one of following composition, all percentage by weight not:
(1) carmustine 1%-40%
(2) slow-release auxiliary material 45%-98.9%
(3) release regulator 0.1%-15%
Total amount is 100%.
Wherein, carmustine can be its various salt, serves as preferred with its hydrochlorate;
The percentage by weight of carmustine in sustained-release implant is 1%-40%, is preferred with 5%-30%, with 10%-25% for choosing is arranged most.
Slow-release auxiliary material can be selected from, but be not limited to for poly-phospholipid, poly-(L-lactide-co-etherophosphoric acid) or poly-(L-lactide-co-phosphoric acid propyl ester);
Wherein, the molecular weight peak value of poly-phospholipid is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000, with 5000-10000,10000-25000,25000-35000 or 30000-50000 serves as preferred, with 10000-25000,25000-35000 or 30000-50000 choosing is arranged most;
Release regulator is selected from a kind of or its combination in mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin; With mannitol, sorbitol, chitin, sodium salt, chrondroitin serves as preferred; The percentage by weight of release regulator in sustained-release implant is 0.1%-15%, is preferred with 0.5%-10%, with 1%-8% for choosing is arranged most.
The consumption of sustained-release implant depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is at the repair ability that can reduce tumor cell, when increasing the chemotherapy action effect and the toxic reaction of not obvious increase medicine.Effective dose is 0.1-300 milligram/patient, is ideal with 1-100 milligram/patient, with 2-50 milligram/patient for the most desirable.
The present invention can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be made into various dosage forms, as, but be not limited to, injection, muddy suspension, ointment, capsule, implant, slow releasing agent and implantation slow release agent etc., wherein implant is mainly sustained-release implant, controlled release implant or slowbreak implant; Be different shape, as, but be not limited to granular, microsphere, nanosphere, lamellar, sphere, bulk, needle-like, bar-shaped and apperance; Can be through various administrations, as in tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.
Whether route of administration depends on multiple factor, as position, tumor place, perform the operation or transfer, gross tumor volume size, tumor classification, patient age, health, bearing status and requirement etc.For obtain active drug concentration in position, tumor place, arterial perfusion optionally, intra-bladder instillation (intracavitary), (intraspinal) administration in abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and the canalis spinalis, but also place in the internal organs, as in the enteric cavity, in the intravesical, uterine cavity, in intravaginal, gastric and the esophagus etc.In various approach, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, to place the form that slowly discharges serve as preferably for tumor week or tumor chamber, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant and sustained-release implant as selecting for use.
Available arbitrary method preparation.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anti-cancer sustained-released implantation agent also can be packed in the liposome.The effective ingredient of sustained-release implant can be packaged in the whole slow-release auxiliary material equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.
Each component and the weight percentage in sustained-release implant thereof are preferred one of following in the sustained-release implant:
(1) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 1%-5%, 95%-99%;
(2) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 5%-10%, 90%-95%;
(3) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 10%-15%, 85%-90%;
(4) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 15%-20%, 80%-85%;
(5) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 20%-35%, 65%-80%;
(6) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 1%-5%, 95%-99%;
(7) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 5%-10%, 90%-95%;
(8) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 10%-15%, 85%-90%;
(9) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 15%-20%, 80%-85%;
(10) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 20%-35%, 65%-80%.
Wherein, the molecular weight peak value of p (LAEG-EOP) is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000; The molecular weight peak value of p (DAPG-EOP) is 1000-10000,10000-25000,25000-40000 or 40000-60000.
Above-mentioned sustained-release implant is granular, microsphere, nanosphere, lamellar, sphere, bulk, needle-like, bar-shaped or mould shape.
In the sustained-release implant each component and the weight percentage in sustained-release implant thereof with one of following for most preferably:
(1) 1% carmustine, 95% poly-(L-lactide-co-etherophosphoric acid), 4% chitin, mannitol or sorbitol;
(2) 5% carmustine, 90% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride, mannitol or chrondroitin;
(3) 10% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 10% chitin, mannitol or sorbitol;
(4) 15% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride, mannitol or chrondroitin;
(5) 20% carmustine, 75% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride, mannitol or sorbitol gather;
(6) 2% carmustine, 90% poly-(L-lactide-co-phosphoric acid propyl ester), 8% chitin, mannitol or sorbitol;
(7) 7.5% carmustine, 85% poly-(L-lactide co-phosphoric acid propyl ester), 7.5% sodium chloride, mannitol or chrondroitin;
(8) 10% carmustine, 75% poly-(L-lactide-co-phosphoric acid propyl ester), 5% chitin, mannitol or sorbitol;
(9) 12.5% carmustine, 70% poly-(L-lactide-co-phosphoric acid propyl ester), 12.5% sodium chloride, mannitol or chrondroitin;
(10) 25% carmustine, 70% poly-(L-lactide-co-phosphoric acid propyl ester), 5% sodium chloride, mannitol or sorbitol gather.
Wherein, the molecular weight peak value of poly-(L-lactide-co-etherophosphoric acid) is 10000-25000,25000-35000 or 30000-50000; The molecular weight peak value of poly-(L lactide-co-phosphoric acid propyl ester) is 10000-25000,25000-40000 or 40000-60000.
Each component and the weight percentage in sustained-release implant thereof also comprise one of following in the most preferred sustained-release implant:
(1) 5% carmustine, 90% poly-(L-lactide-co-etherophosphoric acid), 5% mannitol or sorbitol;
(2) 10% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 10% mannitol;
(3) 10% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 10% sorbitol;
(4) 15% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride or mannitol;
(5) 20% carmustine, 75% poly-(L-lactide-co-etherophosphoric acid), 5% mannitol.
With one of following:
(1) 5% carmustine, 90% poly-(L-lactide-co-phosphoric acid propyl ester), 5% mannitol or sorbitol;
(2) 7.5% carmustine, 85% poly-(L-lactide-co-phosphoric acid propyl ester), 7.5% mannitol;
(3) 10% carmustine, 75% poly-(L-lactide-co-phosphoric acid propyl ester), 5% chitin, mannitol or sorbitol;
(4) 12.5% carmustine, 70% poly-(L-lactide-co-phosphoric acid propyl ester), 12.5% mannitol or chrondroitin;
(5) 15% carmustine, 75% poly-(L-lactide-co-phosphoric acid propyl ester), 5% mannitol or sorbitol gather.
The molecular weight peak value of above-mentioned poly-phosphide is 10000-25000,25000-35000 or 30000-50000.
Sustained-release implant is used for the treatment of entity tumor, comprises the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, osteosarcoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, lymphoma, tumor of head and neck and comes from former or cancer, sarcoma or the carcinosarcoma of secondary of gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes.Therefore, application of the present invention is the above-mentioned various pharmaceutical preparatioies that are used to make the above-mentioned tumor of treatment, serve as preferred wherein with injection, muddy suspension, ointment, capsule, implant, slow releasing agent and sustained-release implant, with sustained-release implant, controlled release implant or slowbreak implant for most preferably.
Also can add other medicinal ingredient in this anti-cancer sustained-released implantation agent, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
Anti-cancer sustained-released implantation agent of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, anti-cancer sustained-released implantation agent of the present invention can be used simultaneously with non-operative treatment, also can in implementing a few days ago, non-operative treatment use, its purpose is to strengthen as far as possible the sensitivity of tumor, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.
When used the part, this sustained-release implant can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.The outer entity tumor of cranium had the obvious treatment effect.
Anti-cancer sustained-released implantation agent of the present invention can be implemented by many schemes, and its purpose is just in order to further specify, and is not in addition any restriction of enforcement of the present invention.
Studies show that the carmustine carmustine is had the obvious suppression effect to multiple solid tumor cell growth.Suppression ratio to growth of tumour cell such as hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, skin carcinoma, lymphoma and carcinoma of testis is 70%-98% (seeing Chinese patent ZL200510043480.0).
The preparation method of sustained-release implant of the present invention is as follows:
1, the slow-release auxiliary material of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as;
2, adding the slow release regulator of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement;
3, adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement;
4, remove organic solvent.Vacuum drying or cold drying all can.
5, dried solid sustained-release implant is made different shape as required.
6, ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
The the 2nd and 3 goes on foot and can carry out simultaneously or with different orders, depends primarily on stability of drug.
(4) specific embodiment
Embodiment one,
(molecular weight is the PLGA of 15000-25000 with the slow-release auxiliary material of weighing, 75: 25) or molecular weight be that poly-(the L-lactide-co-etherophosphoric acid) of 15000-25000 put into different containers respectively, add the carmustine that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(A) 1% carmustine contains 1mg carmustine, 99mgPLGA
(a) 1% carmustine contains 1mg carmustine, poly-(L-lactide-co-etherophosphoric acid);
(B) 5% carmustine, contain 5mg carmustine, 95mgPLGA;
(b) 5% carmustine, contain 5mg carmustine, poly-(L-lactide-co-etherophosphoric acid);
(C) 10% carmustine, contain 10mg carmustine, 90mgPLGA;
(c) 10% carmustine, contain 10mg carmustine, poly-(L-lactide-co-etherophosphoric acid);
(D) 15% carmustine, contain 15mg carmustine, 85mgPLGA;
(d) 15% carmustine, contain 15mg carmustine, poly-(L-lactide-co-etherophosphoric acid);
(E) 20% carmustine, contain 20mg carmustine, 80mgPLGA;
(e) 20% carmustine, contain 20mg carmustine, poly-(L-lactide-co-etherophosphoric acid).
Embodiment two
10 sustained-release implants among the embodiment one are put into the drug accumulation burst size (%) that digestion instrument is measured its different time respectively, found that (A) in the sustained-release implant, (B), (C), (D) and (E) five be that the rate of release of carmustine sustained-release implantation agent of adjuvant is fast with PLGA, 30-40 days, and (a) and (b), (c), (d) and (e) etc. with poly-(L-lactide-co-etherophosphoric acid) be adjuvant the drug slow rate of release of carmustine sustained-release implantation agent slower, be 40-60 days.
Embodiment three
(molecular weight is the PLGA of 20000-30000 with the slow-release auxiliary material of weighing, 75: 25) or molecular weight be that poly-(the L-lactide-co-phosphoric acid propyl ester) of 15000-25000 put into different containers respectively, add the carmustine that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(A) 1% carmustine contains 1mg carmustine, 99mgPLGA
(a) 1% carmustine contains 1mg carmustine, 95mg poly-(L-lactide-co-phosphoric acid propyl ester);
(B) 5% carmustine, contain 5mg carmustine, 95mgPLGA;
(b) 5% carmustine, contain 5mg carmustine, 91mg poly-(L-lactide-co-phosphoric acid propyl ester);
(C) 10% carmustine, contain 10mg carmustine, 90mgPLGA;
(c) 10% carmustine, contain 10mg carmustine, 80mg poly-(L-lactide-co-phosphoric acid propyl ester);
(D) 15% carmustine, contain 15mg carmustine, 85mgPLGA;
(d) 15% carmustine, contain 15mg carmustine, 80mg poly-(L-lactide-co-phosphoric acid propyl ester);
(E) 20% carmustine, contain 20mg carmustine, 80mgPLGA;
(e) 20% carmustine, contain 20mg carmustine, 75mg poly-(L-lactide-co-phosphoric acid propyl ester).
Embodiment four
10 sustained-release implants among the embodiment three are put into the drug accumulation burst size (%) that digestion instrument is measured its different time respectively, found that (A) in the sustained-release implant, (B), (C), (D) and (E) five be that the rate of release of carmustine sustained-release implantation agent of adjuvant is fast with PLGA, 1828 days, and (a) and (b), (c), (d) and (e) or the like with poly-(L-lactide-co-etherophosphoric acid) be adjuvant the drug slow rate of release of carmustine sustained-release implantation agent slower, be 30-50 days.
Embodiment five
With the molecular weight of weighing is that poly-(the L-lactide-co-etherophosphoric acid) or poly-(L-lactide-co-phosphoric acid propyl ester) of 15000-25000 put into different containers respectively, add the carmustine that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(A) 2% carmustine contains 2mg carmustine, 98mg poly-(L-lactide-co-etherophosphoric acid);
(a) 2% carmustine contains 2mg carmustine, 90mg poly-(L-lactide-co-etherophosphoric acid), 8mg sodium chloride;
(B) 7.5% carmustine, contain 7.5mg carmustine, 92.5mg poly-(L-lactide-co-phosphoric acid propyl ester);
(b) 7.5% carmustine, contain 7.5mg carmustine, 85mg poly-(L-lactide-co-phosphoric acid propyl ester), 7.5mg sodium chloride;
(C) 10% carmustine, contain 10mg carmustine, 90mg poly-(L-lactide-co-etherophosphoric acid);
(c) 10% carmustine, contain 10mg carmustine, 90mg poly-(L-lactide-co-phosphoric acid propyl ester);
(D) 12.5% carmustine, contain 12.5mg carmustine, 87.5mg poly-(L-lactide-co-etherophosphoric acid);
(d) 12.5% carmustine, contain 12.5mg carmustine, 75mg poly-(L-lactide-co-etherophosphoric acid), 12.5mg sodium chloride;
(E) 25% carmustine, contain 25mg carmustine, 75mg poly-(L-lactide-co-phosphoric acid propyl ester);
(e) 25% carmustine, contain 25mg carmustine, 70mg poly-(L-lactide-co-phosphoric acid propyl ester), 5mg sodium chloride
Embodiment six
10 sustained-release implants among the embodiment five are put into the drug accumulation burst size (%) that digestion instrument is measured its different time respectively, found that (A) in the sustained-release implant, (B), (D) and (E) four carmustine sustained-release implantation agents that do not contain slow release regulator (sodium chloride) prominent to release phenomenon more obvious, it is prominent releases phenomenon and mostly occurs at 30-50 days, account for the 62-80% of total content of dispersion, and (a), (b), (d) and (e) the prominent phenomenon of releasing of carmustine sustained-release implantation agent that etc. contains slow release regulator (sodium chloride) is obviously not obvious, and drug slow discharges 42-60 days.
Embodiment seven
The slow-release auxiliary material (molecular weight is 25000-40000 poly-(a L-lactide-co-etherophosphoric acid)) of weighing is put into different containers respectively with slow release regulator (mannitol), add the carmustine that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(1) 5% carmustine, 90% PLGA, 5% mannitol;
(2) PLGA of the carmustine of 5%-10%, 80%-93%, 2%-10% mannitol;
(3) PLGA of the carmustine of 10%-15%, 75%-89%, 1%-10% mannitol;
(4) PLGA of the carmustine of 15%-20%, 84%-85%, 1%-5% mannitol;
(5) 20%% carmustine, 75% PLGA, 5% mannitol.
Embodiment eight
Make sustained-release implant by embodiment one, three, five described methods, contained anticancer effective component that different is is one of following:
(1) carmustine of 1%-5%, 90%-98% poly-(L-lactide-co-etherophosphoric acid), sodium chloride or the sorbitol of 1%-5%;
(2) carmustine of 5%-10%, 80%-93% poly-(L-lactide-co-etherophosphoric acid), sodium chloride or the sorbitol of 2%-10%;
(3) carmustine of 10%-15%, 75%-89% poly-(L-lactide-co-etherophosphoric acid), sodium chloride or the sorbitol of 1%-10%;
(4) carmustine of 15%-20%, 84%-85% poly-(L-lactide-co-etherophosphoric acid), sodium chloride or the sorbitol of 1%-5%;
(5) sodium chloride of the carmustine of 20%-35%, 60%-79% poly-(L-lactide-co-etherophosphoric acid), 1%-5% or sorbitol are poly-;
(6) carmustine of 1%-5%, 90%-98% poly-(L-lactide-co-phosphoric acid propyl ester), sodium chloride or the sorbitol of 1%-5%;
(7) carmustine of 5%-10%, 80%-93% poly-(L-lactide-co-phosphoric acid propyl ester), sodium chloride or the sorbitol of 2%-10%;
(8) carmustine of 10%-15%, 75%-89% poly-(L-lactide-co-phosphoric acid propyl ester), sodium chloride or the sorbitol of 1%-10%;
(9) carmustine of 15%-20%, 84%-85% poly-(L-lactide-co-phosphoric acid propyl ester), sodium chloride or the sorbitol of 1%-5%;
(10) carmustine of 20%-35% and poly-with sodium chloride that gathers (L-lactide-co-phosphoric acid propyl ester), 1%-5% or the sorbitol of 60%-79%.
Wherein, the molecular weight peak value of poly-(L-lactide-co-etherophosphoric acid) is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000;
The molecular weight peak value of poly-(L-lactide-co-phosphoric acid propyl ester) is 1000-10000,10000-25000,25000-40000 or 40000-60000.
Embodiment nine
The slow-release auxiliary material (molecular weight is poly-(the L-lactide-co-phosphoric acid propyl ester) of 15000-25000) of weighing is put into different containers respectively with slow release regulator (mannitol), add the carmustine that adds Different Weight behind the certain amount of organic solvent dissolving mixing (being as the criterion) more then, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid sustained-release implant is shaped immediately, obtains following sustained-release implant:
(1) 5% carmustine, 90% poly-(L-lactide-co-phosphoric acid propyl ester), 5% mannitol;
(2) 10% carmustine, 83% poly-(L-lactide-co-phosphoric acid propyl ester), 7% mannitol;
(3) 15% carmustine, 75% poly-(L-lactide-co-phosphoric acid propyl ester), 10% mannitol;
(4) 20% carmustine, 77.5% poly-(L-lactide-co-phosphoric acid propyl ester), 2.5% mannitol;
(5) 25%% carmustine, 70% poly-(L-lactide-co-phosphoric acid propyl ester), 5% mannitol.
The drug release time of above sustained-release implant in external normal saline is 35-55 days, is 35-60 days at the subcutaneous drug release time of mice.All there be not prominent releasing.
Embodiment ten
After the subcutaneous implantation of implant mice among the embodiment one, take out to be placed in the room temperature normal saline with different time and soak, survey the burst size of different time medicine (carmustine), and calculate accumulative total and discharge percent (%).Be shown in Table 1.
Table 1
| Embodiment one | 1 day | 3 days | 5 days | 7 days | 14 days | 21 days | 28 days | 35 days | 42 days | 56 days | 63 days |
| (A) | 2.2 | 7.5 | 14 | 30 | 68 | 86 | 98 | 100 | 100 | 100 | 100 |
| (a) | 2 | 8 | 14 | 20 | 40 | 50 | 60 | 72 | 84 | 96 | 98 |
| (B) | 2.2 | 12 | 18 | 31 | 60 | 86 | 92 | 98 | 100 | 100 | 100 |
| (b) | 2.4 | 12 | 18 | 24 | 48 | 54 | 62 | 76 | 88 | 96 | 100 |
| (C) | 2.1 | 9 | 15 | 28 | 60 | 84 | 98 | 100 | 100 | 100 | 100 |
| (c) | 2.3 | 7.9 | 16 | 23.6 | 42.8 | 56 | 64 | 78 | 84 | 92 | 96 |
| (D) | 3.2 | 8 | 17.2 | 36.8 | 62 | 88 | 98 | 100 | 100 | 100 | 100 |
| (d) | 3 | 7.2 | 18 | 24 | 41 | 52 | 68 | 80 | 90 | 98 | 100 |
| (E) | 3.1 | 13.0 | 19.0 | 47.3 | 68.2 | 94 | 98 | 100 | 100 | 100 | 100 |
| (e) | 3 | 11 | 18 | 26.0 | 39 | 52 | 68 | 82 | 88 | 94 | 96 |
Table 1 discharges data and shows, (A), (B) in the sustained-release implant, (C), (D) and (E) five be that the rate of release of carmustine sustained-release implantation agent of adjuvant is fast with PLGA, 35-42 days, prominent the releasing of part occurred in 20 days-30 days, and (a) and (b), (c), (d) and (e) etc. with poly-(L-lactide-co-etherophosphoric acid) be adjuvant the drug slow rate of release of carmustine sustained-release implantation agent slower, be 40-60 days, dashing forward, it is not obvious to release.This unexpected formation another major technique feature of the present invention of finding is for the better control drug release time provides new guidance.
On this basis, the present invention finds that further body is implanted into carmustine other entity tumors such as lymphoma, osteosarcoma, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer, rectal cancer, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate are had better therapeutical effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
Tumor is implanted into the inhibitory action of carmustine implant to entity tumor
Method and step: tumor cell inoculation is subcutaneous in the right side of mice axillary fossa, and (inoculation back the 14th day) is divided into 11 groups at random with animal, 10 every group when diameter of tumor grows to the 0.8cm left and right sides.Be the normal saline group, contain PLGA carmustine implant group (hereinafter to be referred as carmustine PLGA group), contain the carmustine local injection group (being called for short the poly-phospholipid group of carmustine) of poly-phospholipid.With 70% alcohol disinfecting tumor surface skin, select to cut off the long otch of 1mm apart from tumor lower edge 1cm place, with puncture needle with in the implant implantation tumour tissue.Sew up the incision and prevent that implant from spilling.Put to death animal in 20 days with vernier caliper measurement tumor size after the implant embedding in per 3 days, the back of weighing is complete peels off tumor and claims tumor heavy.Calculate tumor control rate %, DAS.ver1.0 pharmacology software is done statistical procedures.
Tumor control rate=(the average tumor of the average tumor weight/normal saline of 1-administration group group is heavy) * 100%
Embodiment 11 tumors are implanted into the tumor-inhibiting action of carmustine spit of fland sustained-release implant to Mice Bearing Lewis Lung Cancer
The carmustine sustained-release implantation agent that makes with step check embodiment one is to the tumor-inhibiting action of Mice Bearing Lewis Lung Cancer according to the method described above.This experimental result proof carmustine implant can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Carmustine PLGA group (A), (B), (C), (D) and tumor control rate (E) are respectively 36%, 46%, 54%, 62% and 66%; And the poly-phospholipid group (a) and (b) of carmustine, (c), (d) and tumor control rate (e) are respectively 43%, 50%, 64%, 76% and 80%.The P value is all less than 0.001.Repeated experiments P value is all less than 0.001, and difference has the height statistical significance.The tumour inhibiting rate of the poly-phospholipid group of carmustine obviously surpasses carmustine PLGA group, twice experimental result good reproducibility.It should be noted that especially, carmustine group (A), (B), (C), (D) and (E) in, the average weight of animal than the poly-phospholipid group of carmustine (a) and (b), (c), (d) and (e) group obviously alleviate, wherein (C), (D) and (E) in have 10%, 40% and 60% animal dead in advance respectively, and death focused mostly between 25-35 days.Therefore illustrate that prominent the releasing of medicine may be the main cause that causes toxic reaction.And organize no animal dead at the poly-phospholipid group (a) and (b) of carmustine, (c), (d) with (e).This is unexpected finds to constitute another major technique feature of the present invention, provides another new selection and guidance for what use carmustine sustained-release implantation agent treatment entity tumor.
Embodiment 12 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to mouse breast cancer
The carmustine sustained-release implantation agent that makes with step check embodiment three is to the tumor-inhibiting action of mouse breast cancer according to the method described above.The poly-phospholipid group of carmustine of experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Carmustine gathers phospholipid group (a) and (b), (c), (d) and tumor control rate (e) and is respectively 44%, 58%, 70%, 80% and 82%.The P value is all less than 0.001.Repeated experiments P value is all less than 0.001, and difference has the height statistical significance.
Embodiment 13 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to rat liver cancer
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of rat liver cancer.The carmustine implant of experimental result proof various dose is implanted in rat liver cancer (H22) entity tumor and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 50%, 56%, 68%, 74% and 80%.Compare with matched group, the P value is equal to or less than 0.001.
Embodiment 14 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to the mice esophageal carcinoma
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mice esophageal carcinoma.The carmustine implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 42%, 54%, 62%, 70% and 80%.Compare with matched group, the P value is all less than 0.001.
Embodiment 15 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to mouse pancreas cancer
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mouse pancreas cancer.The carmustine implant of experimental result proof various dose is implanted in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 31%, 42%, 54%, 62% and 79%, compares with matched group, and the P value is all less than 0.001.
Embodiment 16 carmustine sustained-release implantation agents are to the tumor-inhibiting action of the subcutaneous plantation ovarian cancer of mice
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the mice tumor-inhibiting action of plantation ovarian cancer down.The carmustine implant of experimental result proof various dose is implanted in rat liver cancer (H22) entity tumor and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 32%, 46%, 60%, 72% and 82%.Compare with matched group, the P value is equal to or less than 0.001.
Embodiment 17 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to mouse cervical cancer
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mouse cervical cancer.The carmustine implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 42%, 52%, 74%, 78% and 84%.Compare with matched group, the P value is all less than 0.001.
Embodiment 18 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to the mice carcinoma of prostate
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mice carcinoma of prostate.The carmustine implant of experimental result proof various dose is implanted in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 34%, 44%, 57%, 64% and 78%, compares with matched group, and the P value is all less than 0.001.
Embodiment 19 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to Mouse Gastric Cancer
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of Mouse Gastric Cancer.The carmustine implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 50%, 52%, 76%, 78% and 86%.Compare with matched group, the P value is all less than 0.001.
Embodiment 20 tumors are implanted into the tumor-inhibiting action of carmustine sustained-release implantation agent to mouse junction cancer
The carmustine sustained-release implantation agent that makes according to embodiment 11 and 12 described methods and step check embodiment nine is to the tumor-inhibiting action of mouse junction cancer.The carmustine implant of experimental result proof various dose is implanted in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.5%, the tumor control rate of 10%, 15%, 20% and 25% carmustine implant is respectively 38%, 46%, 50%, 58% and 78%, compares with matched group, and the P value is all less than 0.001.
In addition, tumor is implanted into the carmustine sustained-release implantation agent that contains the slow release regulator other entity tumors such as bladder cancer, carcinoma of testis, colon cancer, carcinoma of endometrium, osteosarcoma, nasopharyngeal carcinoma, renal carcinoma is also had good therapeutical effect, and its effect obviously surpasses equivalent not carmustine sustained-release implantation agent and the carmustine lumbar injection group and the local injection group of slow release regulator.This is unexpected finds to constitute another major technique feature of the present invention, for the treatment of entity tumor provides another new selection.
The foregoing description is to be used for illustrating and also unrestricted the present invention that concrete performance is based on claim.
Claims (10)
1. carmustine sustained-release implantation agent for the treatment of entity tumor is characterized in that this sustained-release implant is made up of one of following composition, all percentage by weight not:
(1) carmustine 1%-40%
(2) slow-release auxiliary material 45%-98.9%
(3) release regulator 0-15%
Total amount is 100%, and wherein, slow-release auxiliary material is poly-phospholipid, is selected from poly-(L-lactide-co-etherophosphoric acid) or poly-(L-lactide-co-phosphoric acid propyl ester); Release regulator is selected from a kind of or its combination in mannitol, sorbitol, xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.
2. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(1) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 1%-5%, 95%-99%;
(2) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 5%-10%, 90%-95%;
(3) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 10%-15%, 85%-90%;
(4) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 15%-20%, 80%-85%;
(5) poly-(the L-lactide-co-etherophosphoric acid) of the carmustine of 20%-35%, 65%-80%;
(6) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 1%-5%, 95%-99%;
(7) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 5%-10%, 90%-95%;
(8) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 10%-15%, 85%-90%;
(9) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 15%-20%, 80%-85%;
(10) poly-(the L-lactide-co-phosphoric acid propyl ester) of the carmustine of 20%-35%, 65%-80%.
3. according to claim 1 and 2 described sustained-release implants, the molecular weight peak value that it is characterized in that described poly-phospholipid is 500-5000,5000-10000,10000-25000,25000-35000 or 30000-50000.
4. according to claim 1 and 2 described sustained-release implants, it is characterized in that this sustained-release implant is granular, microsphere, nanoparticle, lamellar, sphere, bulk, needle-like, bar-shaped or mould shape.
5. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(1) 1% carmustine, 95% poly-(L-lactide-co-etherophosphoric acid), 4% chitin, mannitol or sorbitol;
(2) 5% carmustine, 90% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride, mannitol or chrondroitin;
(3) 10% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 10% chitin, mannitol or sorbitol;
(4) 15% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride, mannitol or chrondroitin;
(5) 20% carmustine, 75% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride, mannitol or sorbitol gather;
(6) 2% carmustine, 90% poly-(L-lactide-co-phosphoric acid propyl ester), 8% chitin, mannitol or sorbitol;
(7) 7.5% carmustine, 85% poly-(L-lactide-co-phosphoric acid propyl ester), 7.5% sodium chloride, mannitol or chrondroitin;
(8) 10% carmustine, 75% poly-(L-lactide-co-phosphoric acid propyl ester), 5% chitin, mannitol or sorbitol;
(9) 12.5% carmustine, 70% poly-(L-lactide-co-phosphoric acid propyl ester), 12.5% sodium chloride, mannitol or chrondroitin;
(10) 25% carmustine, 70% poly-(L-lactide-co-phosphoric acid propyl ester), 5% sodium chloride, mannitol or sorbitol gather.
6. the sustained-release implant according to claim 5, the molecular weight peak value that it is characterized in that described poly-phospholipid is 10000-25000,25000-35000 or 30000-50000.
7. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(1) 5% carmustine, 90% poly-(L-lactide-co-etherophosphoric acid), 5% mannitol or sorbitol;
(2) 10% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 10% mannitol;
(3) 10% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 10% sorbitol;
(4) 15% carmustine, 80% poly-(L-lactide-co-etherophosphoric acid), 5% sodium chloride or mannitol;
(5) 20% carmustine, 75% poly-(L-lactide-co-etherophosphoric acid), 5% mannitol.
8. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(1) 5% carmustine, 90% poly-(L-lactide-co-phosphoric acid propyl ester), 5% mannitol or sorbitol;
(2) 7.5% carmustine, 85% poly-(L-lactide-co-phosphoric acid propyl ester), 7.5% mannitol;
(3) 10% carmustine, 75% poly-(L-lactide-co-phosphoric acid propyl ester), 5% chitin, mannitol or sorbitol;
(4) 12.5% carmustine, 70% poly-(L-lactide-co-phosphoric acid propyl ester), 12.5% mannitol or chrondroitin
(5) 15% carmustine, 75% poly-(L-lactide-co-phosphoric acid propyl ester), 5% mannitol or sorbitol gather.
9. the sustained-release implant according to claim 7-8, the molecular weight peak value that it is characterized in that described poly-phosphide is 10000-25000,25000-35000 or 30000-50000.
10. the sustained-release implant according to claim 1, the anticancer effective component that it is characterized in that this sustained-release implant are used to prepare the treatment cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, osteosarcoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, skin carcinoma, lymphoma, tumor of head and neck and come from the medicine of cancer, sarcoma or the carcinosarcoma of peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node former or secondary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007102028853A CN100563644C (en) | 2007-12-06 | 2007-12-06 | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2007102028853A CN100563644C (en) | 2007-12-06 | 2007-12-06 | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101176707A true CN101176707A (en) | 2008-05-14 |
| CN100563644C CN100563644C (en) | 2009-12-02 |
Family
ID=39403228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2007102028853A Expired - Fee Related CN100563644C (en) | 2007-12-06 | 2007-12-06 | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100563644C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610670A (en) * | 2013-11-04 | 2014-03-05 | 鲁东大学 | Application of carmustin in preparation of medicine for treating lymjphoma |
| CN107375246A (en) * | 2017-07-21 | 2017-11-24 | 浙江理工大学 | A kind of polymer nano-particle preparation method of the load cancer therapy drug with targeting controlled release function |
| WO2019094819A3 (en) * | 2017-11-09 | 2020-03-26 | Abon Pharmaceuticals, Llc | Intravenous delivery systems for chemotherapy drugs |
-
2007
- 2007-12-06 CN CNB2007102028853A patent/CN100563644C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610670A (en) * | 2013-11-04 | 2014-03-05 | 鲁东大学 | Application of carmustin in preparation of medicine for treating lymjphoma |
| CN107375246A (en) * | 2017-07-21 | 2017-11-24 | 浙江理工大学 | A kind of polymer nano-particle preparation method of the load cancer therapy drug with targeting controlled release function |
| CN107375246B (en) * | 2017-07-21 | 2019-10-08 | 浙江理工大学 | A kind of polymer nano-particle preparation method of the load anticancer drug with targeting controlled release function |
| WO2019094819A3 (en) * | 2017-11-09 | 2020-03-26 | Abon Pharmaceuticals, Llc | Intravenous delivery systems for chemotherapy drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100563644C (en) | 2009-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101185633A (en) | Neratinib sustained-release implant for treating solid tumor | |
| CN100563644C (en) | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor | |
| CN101176713B (en) | Carmustine sustained-release implantation agent for curing entity tumour | |
| CN101181230A (en) | Estramustine sustained-release implantation agent for curing entity tumour | |
| CN101219102A (en) | Lapatinib sustained-release implantation agent for treating solid tumors | |
| CN101185627B (en) | Nilotinib sustained-release implant for treating solid tumor | |
| CN101204365A (en) | Implant agent treating for solid tumor | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
| CN101204367A (en) | Axitinib sustained-release implplant treating for solid tumor | |
| CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN101224185A (en) | Bosutinib sustained release implant for treating solid tumors | |
| CN101204366A (en) | Melphalan sustained-release implant treating for solid tumor | |
| CN101176714A (en) | Meifaron sustained-release implantation agent for curing entity tumour | |
| CN101181229A (en) | Busulfan sustained-release implantation agent for curing entity tumour | |
| CN100586435C (en) | Carmofur sustained-release implantation agent for curing entity tumour | |
| CN101176712A (en) | Nimustine sustained-release implantation agent for curing entity tumour | |
| CN101176709A (en) | Beisalutin sustained-release implantation agent for curing entity tumour | |
| CN101204369A (en) | Sorafenib sustained-release implant treating for solid tumor | |
| CN101181231B (en) | Sustained-release implantation agent of urotrotiken | |
| CN101219105A (en) | Emtricitabine sustained-release implantation agent for treating solid tumors | |
| CN101181235B (en) | Tantudinun sustained-release implantation agent for curing entity tumour | |
| CN101185625B (en) | Rubitecan sustained-release implant for treating solid tumor | |
| CN101185632A (en) | Lonafarnib sustained-release implant for treating solid tumor | |
| CN101181234B (en) | Literdinun sustained-release implantation agent for curing entity tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. Address before: 202, room 2, building 19, Pioneer Park, No. 250100 Huaneng Road, Shandong, Ji'nan Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LANJIN BIOENGINEERING CO., LTD. Free format text: FORMER OWNER: JINAN SHUAIHUA MEDICINE TECHNOLOGY CO., LTD. Effective date: 20120815 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120815 Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd. Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 Patentee before: Jinan Shuaihua Pharmaceutical Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091202 Termination date: 20161206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |